Alzinova's CEO Kristina Torfgård has informed the Board of Directors that she wishes to step down as CEO of the company. Kristina will continue to focus on completing the phase 1b clinical study and preparing Alzinova for a phase 2 study with ALZ-101 until she leaves her position on July 31, 2024. The Board of Directors will initiate the search for Kristina's successor immediately.

Kristina has, with great commitment and success during her four and a half years as CEO of Alzinova, brought the company's vaccine candidate ALZ-101 to a phase 1b clinical study. With Kristina's leadership, ALZ-101 has completed part A1 of the clinical study with good results showing high safety and tolerability in patients, which is the primary objective of the phase 1b study. Alzinova has also, under Kristina's leadership, initiated two extension parts of the phase 1b study with the aim of obtaining valuable information for a future phase 2 study.